Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
CA 2440480 A1 · Owner: Fink, Mitchell P. · Inventors: Ulloa, Luis; Tracey, Kevin J.; Fink, Mitchell P.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid a physiologically acceptable salt , of an alpha-ketoalkanoic acid an ester of an alpha-ketoalkanoic acid or an , amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by for , example, an "early" (Tumor Necrosis Factor (TNF) interleukin-1.beta.) or , "late" …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 15, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.